Skip to main content
SpringerLink
Log in

Blood Pressure Management in Diabetic Kidney Disease

  • Chapter
  • First Online:
Diabetic Kidney Disease

  • 555 Accesses

Abstract

Diabetic kidney disease is the leading cause of end-stage kidney disease. Patients with diabetic kidney disease are at extremely high risk for cardiovascular disease. Tight blood pressure control is a key component for prevention of progression of kidney disease and cardiovascular events as well. If strict blood pressure control and blood sugar level control can be accomplished at least until microalbuminuria levels are achieved, in addition to inhibition of the onset and progression of nephropathy, remission induction can also be expected.

The blood pressure reduction target for both patients with diabetic kidney disease and those with hypertension complicating diabetes is below 130/80 mmHg.

The recommended antihypertensive drug of first choice is renin-angiotensin (RA) inhibitors.

It has not been established that RA inhibitors are effective in controlling nephropathy.

A wide diversity of nephropathies are experienced by diabetes patients, and as a result individualized therapy for the purpose of blood pressure control that takes into account the patient’s age, complications, and other factors is important.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Umemura S, Arima H, Arima S, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019;42:1235–481.

    Article  Google Scholar 

  2. Okada H, Research Team for a Grant-in-Aid for Research on Advanced Chronic Kidney Disease, Practical Research Project for Renal Diseases from Japan Agency for Medical Research, et al. Essentials from clinical practice guidelines for CKD stage G3b-5 2017. Clin Exp Nephrol. 2018;22:245–8.

    Article  Google Scholar 

  3. Kashihara N, Haruna Y, Kondeti VK, et al. Oxidative stress in diabetic nephropathy. Curr Med Chem. 2010;17:4256–69.

    Article  CAS  Google Scholar 

  4. Satoh M, Kobayashi S, Kuwabara A, et al. In vivo visualization of glomerular microcirculation and hyperfiltration in streptozotocin-induced diabetic rats. Microcirculation. 2010;17:103–12.

    Article  CAS  Google Scholar 

  5. Parving HH, Kastrup H, Smidt UM, et al. Impaired autoregulation of glomerular filtration rate in type 1 (insulin-dependent) diabetic patients with nephropathy. Diabetologia. 1984;27:547–52.

    Article  CAS  Google Scholar 

  6. Ichihara A, Kaneshiro Y, Takemitsu T, et al. The (pro)renin receptor and the kidney. Semin Nephrol. 2007;27:524–8.

    Article  CAS  Google Scholar 

  7. Satoh M, Fujimoto S, Haruna Y, et al. NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am J Physiol Renal Physiol. 2005;288:F1144–52.

    Article  CAS  Google Scholar 

  8. Satoh M, Fujimoto S, Arakawa S, et al. Angiotensin II type 1 receptor blocker ameliorates uncoupled endothelial nitric oxide synthase in rats with experimental diabetic nephropathy. Nephrol Dial Transplant. 2008;23:3806–13.

    Article  CAS  Google Scholar 

  9. Kidokoro K, Satoh M, Channon KM, et al. Maintenance of endothelial guanosine triphosphate cyclohydrolase I ameliorates diabetic nephropathy. J Am Soc Nephrol. 2013;24:1139–50.

    Article  CAS  Google Scholar 

  10. Group Accord Study, Group Accord Eye Study Group, Chew EY, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363:233–44.

    Article  Google Scholar 

  11. Bangalore S, Kumar S, Lobach I, et al. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. Circulation. 2011;123:2799–810.

    Article  CAS  Google Scholar 

  12. Arima H, Anderson C, Omae T, et al. Effects of blood pressure lowering on major vascular events among patients with isolated diastolic hypertension: the perindopril protection against recurrent stroke study (PROGRESS) trial. Stroke. 2011;42:2339–41.

    Article  CAS  Google Scholar 

  13. Kokubo Y, Kamide K, Okamura T, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease in a Japanese urban cohort: the Suita study. Hypertension. 2008;52:652–9.

    Article  CAS  Google Scholar 

  14. Rahman M, Ford CE, Cutler JA, et al. Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR. Clin J Am Soc Nephrol. 2012;7:989–1002.

    Article  Google Scholar 

  15. Jandeleit-Dahm KA, Tikellis C, Reid CM, et al. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens. 2005;23:463–73.

    Article  CAS  Google Scholar 

  16. Andersen S, Brochner-Mortensen J, Parving HH, et al. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diabetes Care. 2003;26:3296–302.

    Article  Google Scholar 

  17. Makino H, Haneda M, Babazono T, et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care. 2007;30:1577–8.

    Article  CAS  Google Scholar 

  18. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9.

    Article  CAS  Google Scholar 

  19. Imai E, Chan JC, Ito S, et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia. 2011;54:2978–86.

    Article  CAS  Google Scholar 

  20. Kurokawa K, Chan JC, Cooper ME, et al. Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study. Clin Exp Nephrol. 2006;10:193–200.

    Article  CAS  Google Scholar 

  21. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351:1941–51.

    Article  CAS  Google Scholar 

  22. Hollenberg NK, Fisher ND. Renal circulation and blockade of the renin-angiotensin system. Is angiotensin-converting enzyme inhibition the last word? Hypertension. 1995;26:602–9.

    Article  CAS  Google Scholar 

  23. Esnault VL, Ekhlas A, Delcroix C, et al. Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. J Am Soc Nephrol. 2005;16:474–81.

    Article  CAS  Google Scholar 

  24. Bakris GL, Toto RD, McCullough PA, et al. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int. 2008;73:1303–9.

    Article  CAS  Google Scholar 

  25. Suzuki H, Saruta T. Effects of calcium antagonist, benidipine, on the progression of chronic renal failure in the elderly: a 1-year follow-up. Clin Exp Hypertens. 2001;23:189–201.

    Article  CAS  Google Scholar 

  26. Investigators Ontarget, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–59.

    Article  Google Scholar 

  27. Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204–13.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama Prefecture, Japan

    Naoki Kashihara

Authors
  1. Naoki Kashihara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Naoki Kashihara .

Editor information

Editors and Affiliations

  1. Department of Nephrology and Laboratory, Kanazawa University, Kanazawa, Ishikawa, Japan

    Takashi Wada

  2. Department of Nephrology, Kanazawa Medical University, Kanazawa, Ishikawa, Japan

    Kengo Furuichi

  3. Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan

    Naoki Kashihara

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kashihara, N. (2021). Blood Pressure Management in Diabetic Kidney Disease. In: Wada, T., Furuichi, K., Kashihara, N. (eds) Diabetic Kidney Disease. Springer, Singapore. https://doi.org/10.1007/978-981-15-9301-7_5

Download citation

  • DOI: https://doi.org/10.1007/978-981-15-9301-7_5

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-15-9300-0

  • Online ISBN: 978-981-15-9301-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation